GlassScriptPhysician profile
Kayla Hopper Guyette
NPI 1568028884
$8,812.06
in general payments reported to CMS, 2019-2025
6 companies · $6,174 in 2025
The $6,174 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $102 · 2022: $1,336 · 2023: $434 · 2024: $766 · 2025: $6,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,800 · Food and Beverage: $2,602 · Travel and Lodging: $972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,800.00 |
| Food and Beverage | $2,602.02 |
| Travel and Lodging | $971.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $8,543.93 | 2022-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve, Pascal |
| Pfizer INC. | $146.63 | 2021-2025 | |
| Boston Scientific Corporation | $67.56 | 2022-2023 | Resonate El Icd Vr, Watchman Access System |
| Novartis Pharmaceuticals Corporation | $21.92 | 2023 | |
| Octapharma USA, INC. | $18.13 | 2025 | Fibryga |
| Astrazeneca Pharmaceuticals LP | $13.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Guyette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.